CoRegen
Early-stage biotechnology company developing gene-engineered regulatory T cell (Treg) therapies and in vivo gene-engineering biologics for solid tumors. Core activities include preclinical evaluation in multiple aggressive tumor models, development of autologous cell manufacturing workflows, regulatory engagement toward IND/Phase 1 trials, and the pursuit of both cell‑based and in‑vivo gene editing platforms.
Industries
Nr. of Employees
medium (51-250)
CoRegen
Aspen, Colorado, United States, North America
Products
CRG-150 Adoptive Treg Cell Therapy (autologous gene‑edited Treg)
Autologous Treg cell therapy generated by isolating a patient’s Treg cells, applying targeted gene disruption to a regulatory gene, expanding and formulating cells for outpatient infusion to target solid tumors.
In vivo gene-editing injectable biologic (developmental)
An investigational injectable biologic platform intended to perform gene editing directly in target cells in vivo using a Cas9 fusion protein paired with targeting antibodies and guide RNAs, intended as an alternative to ex vivo adoptive cell transfer.
CRG-150 Adoptive Treg Cell Therapy (autologous gene‑edited Treg)
Autologous Treg cell therapy generated by isolating a patient’s Treg cells, applying targeted gene disruption to a regulatory gene, expanding and formulating cells for outpatient infusion to target solid tumors.
In vivo gene-editing injectable biologic (developmental)
An investigational injectable biologic platform intended to perform gene editing directly in target cells in vivo using a Cas9 fusion protein paired with targeting antibodies and guide RNAs, intended as an alternative to ex vivo adoptive cell transfer.
Expertise Areas
- Cell therapy development
- Gene editing and in vivo gene engineering
- Preclinical oncology models and in vivo efficacy testing
- Clinical trial design and outpatient infusion operations
Key Technologies
- Targeted gene knockout/editing (gene disruption in Treg cells)
- CRISPR/Cas-based fusion protein in vivo editing
- Autologous adoptive cell transfer workflows
- Leukapheresis and cell isolation
News & Updates
Announcement that the company's CRG-150 program received FDA clearance to proceed into Phase 1/2a clinical trials for multiple solid tumor types.
Publication and press release describing promising new preclinical data supporting the engineered Treg platform as an immunotherapy approach.
Company announcement of a >$93M financing round to support development activities.
Leadership appointment to the role of Chief Medical Officer.
Recognition by the Proceedings of the National Academy of Sciences (PNAS) with the 2023 Cozzarelli Prize for an outstanding paper relevant to the company's science.
Announcement that the company's CRG-150 program received FDA clearance to proceed into Phase 1/2a clinical trials for multiple solid tumor types.
Publication and press release describing promising new preclinical data supporting the engineered Treg platform as an immunotherapy approach.
Company announcement of a >$93M financing round to support development activities.
Leadership appointment to the role of Chief Medical Officer.
Recognition by the Proceedings of the National Academy of Sciences (PNAS) with the 2023 Cozzarelli Prize for an outstanding paper relevant to the company's science.